Tumor delivery of macromolecular drugs based on the EPR effect

被引：1639

作者：

Torchilin, Vladimir ^{[1
]}

机构：

[1] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2011年 / 63卷 / 03期

关键词：

Tumors; Drug delivery; EPR effect; Protein drugs; Peptide drugs; Polymeric drugs; Pharmaceutical nanocarriers; Tumor targeting; Intracellular drug delivery; PEGYLATED-LIPOSOMAL DOXORUBICIN; LONG-CIRCULATING LIPOSOMES; PHASE-II TRIAL; IN-VIVO; ENHANCED PERMEABILITY; TARGETED DELIVERY; VASCULAR-PERMEABILITY; POLYMERIC MICELLES; SOLID TUMORS; CANCER;

D O I：

10.1016/j.addr.2010.03.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Enhanced permeability and retention (EPR) effect is the physiology-based principal mechanism of tumor accumulation of large molecules and small particles. This specific issue of Advanced Drug Delivery Reviews is summing up multiple data on the EPR effect-based drug design and clinical outcome. In this commentary, the role of the EPR effect in the intratumoral delivery of protein and peptide drugs, macromolecular drugs and drug-loaded long-circulating pharmaceutical nanocarriers is briefly discussed together with some additional opportunities for drug delivery arising from the initial EPR effect-mediated accumulation of drug-containing macromolecular systems in tumors. (C) 2010 Elsevier B.V. All rights reserved.

引用

页码：131 / 135

页数：5

共 84 条

[1]

ABUCHOWSKI A, 1984, CANCER BIOCHEM BIOPH, V7, P175

[2]

Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139

[3] PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].

ALLEN, TM ;

HANSEN, C .

BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141

[4]

Asselin BL, 1999, ADV EXP MED BIOL, V457, P621

[5] Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy [J].

Bae, Y ;

Nishiyama, N ;

Fukushima, S ;

Koyama, H ;

Yasuhiro, M ;

Kataoka, K .

BIOCONJUGATE CHEMISTRY, 2005, 16 (01) :122-130

[6] Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging [J].

Bartlett, Derek W. ;

Su, Helen ;

Hildebrandt, Isabel J. ;

Weber, Wolfgang A. ;

Davis, Mark E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) :15549-15554

[7] Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art [J].

Bondi, Maria Luisa ;

Craparo, Emanuela Fabiola .

EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (01) :7-18

[8] Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study [J].

Bukowski, R ;

Ernstoff, MS ;

Gore, ME ;

Nemunaitis, JJ ;

Amato, R ;

Gupta, SK ;

Tendler, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3841-3849

[9] Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer [J].

Danson, S ;

Ferry, D ;

Alakhov, V ;

Margison, J ;

Kerr, D ;

Jowle, D ;

Brampton, M ;

Halbert, G ;

Ranson, M .

BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2085-2091

[10] Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody [J].

El Bayoumil, TamerA. ;

Torchilin, Vladimir P. .

CLINICAL CANCER RESEARCH, 2009, 15 (06) :1973-1980

← 1 2 3 4 5 6 7 8 9 →